Previous 10 | Next 10 |
2024-03-05 11:33:18 ET More on Quoin Pharmaceuticals Quoin stock soars 60% on FDA update for ichthyosis drug Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical earnings data for Quoin Pharmaceuticals Financial information for Quoin Pharma...
2024-03-05 10:02:11 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-05 08:31:33 ET Losers: Quoin Pharmaceuticals Ltd ( QNRX ) -43% announces pricing of $6.5 Million public offering. GigCapital5 ( QTI ) -43% . Gitlab GTLB -23% after Q4 earnings release . SEMrush Holdings SEMR -17% . after Q4 earnings re...
ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering o...
2024-03-04 09:06:31 ET DENVER, Colo., Mar 04, 2024 ( 247marketnews.com )- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX ) reported, this morning, that the U.S. Food and Drug Administration (FDA) cleared the Company to recruit teen subjects aged 14 years and older into its two ongoing cli...
Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more robust data set This important development represents the first e...
2024-02-12 17:28:31 ET More on Quoin Pharmaceuticals Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical earnings data for Quoin Pharmaceuticals Financial information for Quoin Pharmaceuticals Read the full article on Seeking Alpha ...
ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan dise...
Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower dose eliminated from blinded trial Dosing frequency changed to twice-daily from once-daily for both trials ASHBURN, Va., Dec. 13, 20...
2023-11-09 10:59:32 ET More on Quoin Pharmaceuticals Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical earnings data for Quoin Pharmaceuticals Financial information for ...
News, Short Squeeze, Breakout and More Instantly...
Quoin Pharmaceuticals Ltd. Company Name:
QNRX Stock Symbol:
NASDAQ Market:
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles technology and other approaches will be utilized to optimize the local delivery ...
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late 2025 ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals...
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty p...